NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2
NRAS mutation	Cutaneous Melanoma	NRAS mutation	Cutaneous Melanoma	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2
NRAS mutation	Myelodysplastic Syndrome	NRAS mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
NRAS mutation	Thyroid Gland Medullary Carcinoma	NRAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	azacitidine Resistant: B - Late Trials azacitidine Resistant : B	azacitidine Resistant: B - Late Trials azacitidine Resistant : B
NRAS mutation	Melanoma	NRAS mutation	Melanoma	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B
NRAS mutation	Melanoma	NRAS mutation	Melanoma	trametinib + ERAS-254 Sensitive: B - Late Trials trametinib + ERAS-254 Sensitive : B	trametinib + ERAS-254 Sensitive: B - Late Trials trametinib + ERAS-254 Sensitive : B
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2

NRAS mutation

Associations